{"name":"Arjil Pharmaceuticals LLC","slug":"arjil-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"Arjil Pharmaceuticals LLC is a biopharmaceutical company focused on the development of innovative treatments. Despite having one drug in its pipeline, AR100DP1, the company has discontinued its development, indicating a shift in strategic focus or challenges in advancing the program.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQdEFnQktFM210eXdiZmRhVlE4Y3FUTndfak5Cell5OFgyR1Z1QWxsaks4TzU0NTBvZlJIc0o3enpwWTlTYXBFR3o4eFZNZUg2QUpEZGN5Z3ZsTFRqTmZOMVBSZVpoa1YxT3ZHbFlaVVJOZHBWZjFkSE1jSFpXSVVpYVl2U1VhSHRJS1daVHZkSHAtLW5nbW1aeWZIZk9CQUxLNnVlYVF6VVZNRVdtT3ZpVzhMVkI1ODFPLUpqLWpBU3dEVnpWSldBX1JaTmZaX1VTUFJEc0hubWtXZGVwWmw4UmlyLUpTbk5MYVhCRENwaVByRVhzZXhobF9wUGJNYzUtMGNzWEFqbkN3enFKdFplVjJnYzVPQVduMDAzZ1Jn?oc=5","date":"2025-12-08","type":"regulatory","source":"GlobeNewswire","summary":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma - GlobeNewswire","headline":"Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOSkFOUFNlZC1BR0tYYkdSdGdWREZHMGZPR1d3U2J5czVzMFZhX0N4SFhkcWw5V3pfS3BvSzNsZGdFRElyUGkxd1RyREd1SkJ0X2FVSy1tZW94OHdWclVBTlNkMy1TSWlQNE9IUGRSQnJaazZ6U1FrYUQ1bFYzNUFLdkZ5djdFXzZyd0RlQldLWlIxc3daNXAtMjNzbG5xWklRd1hUMkM5S29VZUxrSkRCUlY3eHN2SzB5YndTRG1aQ05CMVZ6Wlg2Z2oweE9uVWlkNVk1Q01Dd0pRcXhrb2p3ZXJ1cFJqRFJsbWllWU1rbURVOWFYU0R6bm0yVXg?oc=5","date":"2025-05-12","type":"trial","source":"PR Newswire","summary":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"Chronic Pruritus Market is Anticipated to Expand at a CAGR of 8.6% During the Study Period (2020-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQT0pkMkxEYXAzQmNNOEFLNkN1S1RaazBYUGdNS29VVjNDeXotZEpuUGRKSURyQi1LY1dhWGJvcnJ1d2s0VEw4ZUhSSDNCZTBmZzJxcWJrUkdycUpuV0lmOEFNakFpT2otaEcyLWZlX0F6cVV1Q0dxczZXY0VJbUYzVTFlR2dHYkExTXFzdnYxZ3ZlZWpBV2xSamFXcklJejNFQmhvQ2RTT2ZwLU9meXoxa1dGQ2ZwTzZZRHRzR1d4OFE4WXctVzFPWHBQZi1MYXl6NENOTGxmWG53eWdDYVUwM2lhQVBIM04zRnhfUVE1dVE0dG5WUnNzaTF4X2hyUXhwekFkT1hjakRJUTFLNVNGcmRrN2xwMnNfX0dTdnEwSXowRFExOGY1NkNOalJieDFtRVhnTzFlMHQwUUZ3S1pSWXNSNERvZUtx?oc=5","date":"2025-03-03","type":"trial","source":"GlobeNewswire","summary":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}